Loading news...
Mayne Pharma Group (OTCMKTS:MAYNF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent
Mayne Pharma Group Limited (MAYNF) Discusses U.S. Launch and Business Model of DistributeRx Transcript
Mayne Pharma Group Limited (MAYNF) Q2 2026 Earnings Call Transcript
Mayne Pharma Group Limited (OTCMKTS:MAYNF - Get Free Report)'s stock price was up 1.4% on Thursday. The stock traded as high as $1.8550 and last traded at $1.8550. Approximately 731 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 5,454 shares. The stock had previously closed at
Mayne Pharma Group Limited (MAYNF) Shareholder/Analyst Call Transcript
Mayne Pharma Group Limited (OTCMKTS:MAYNF - Get Free Report)'s stock price fell 9.7% on Monday. The stock traded as low as $2.13 and last traded at $2.13. 150 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 3,106 shares. The stock had previously closed at $2.36. Mayne
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma Group Limited (Mayne Pharma, ASX: Ticker MYX) terminating the agreement between Cosette and Mayne Pharma under which Cosette was to acquire all the outstanding shares of Mayne Pharma (Scheme Implementation Deed). Cosette also notes the announcements from Mayne Pharma on 10 December 2025 and 11 Dece.
Australia's government said it would block a $387.2 million takeover of Mayne Pharma by U.S. company Cosette Pharmaceuticals on national security grounds, citing a need to protect critical medical supply chains.
Australia on Friday blocked a A$672 million ($433 million) buyout offer for Mayne Pharma from U.S. drugmaker Cosette Pharmaceuticals, citing national interest.
Australia's Mayne Pharma said on Friday it had received a letter from its potential acquirer, Cosette, indicating that the country's treasurer is considering blocking the A$672 million ($436.67 million) proposed buyout of the company.
An Australian court has moved to prevent U.S. drugmaker Cosette Pharmaceuticals from abandoning its A$672 million ($437.6 million) acquisition of Mayne Pharma , the ASX-listed company said on Thursday.
Shares of Mayne Pharma plunged 30% on Wednesday after U.S.-based Cosette Pharmaceuticals initiated a review of its A$672 million ($432.1 million) acquisition, citing a "material adverse change" in the Australian firm's business and finances.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma's Board of Directors has unanimously recomm.
Proposed Ruling Aims to Eliminate Out-of-Pocket Costs for Contraception, Enhancing Access for Women in the United States ADELAIDE, Australia and RALEIGH, N.C. , Nov. 4, 2024 /PRNewswire/ -- Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), welcomes the Biden-Harris Administration's newly proposed rule to expand coverage of affordable contraception under the Affordable Care Act (ACA).
Mayne Pharma has filed a patent infringement lawsuit against Indian drugmaker Sun Pharma in a U.S. court, the Australian drugmaker said on Thursday.
Mayne Pharma Group Limited (OTCPK:MAYNF) Q2 2024 Results Conference Call February 25, 2024 5:00 PM ET